1. Williams DM, et al. Acute kidney failure: a pediatric experience over 20 years. Archives of Pediatric & Adolescent Medicine 2002; 156: 893–900.
2. Siegler RL, et al. Long-term outcome and prognostic indicators in the haemolytic-uraemic syndrome. Journal of Pediatrics 1991; 118: 195–200.
3. Garg AX, et al. Long-term renal prognosis of diarrhea-associated hemolytic uremic syndrome: a systematic review, meta-analysis, and meta-regression. Journal of the American Medical Association 2003; 290: 1360–1370.
4. Tarr PI, Gordon CA, Chandler WL. Shiga toxin-producing Escherichia coli and the haemolytic uraemic syndrome. Lancet 2005; 365: 1073–1086.
5. Lynn RM, et al. Childhood hemolytic uremic syndrome, United Kingdom and Ireland. Emerging Infectious Disease 2005; 11: 590–596.
6. Tsai HM, Lian EC. Antibodies to von Willebrand factor-cleaving protease in acute thrombotic thrombocytopenic purpura. New England Journal of Medicine 1998; 339: 1585–94.
7. Furlan M, et al. von Willebrand factor-cleaving protease in thrombotic thrombocytopenic purpura and the hemolytic-uremic syndrome. New England Journal of Medicine 1998; 339: 1578–84.
8. Levy GG, et al. Mutations in a member of the ADAMTS gene family causing thrombotic thrombocytopenic purpura. Nature 2001; 413: 488–494.
9. Tsai HM, et al. von Willebrand factor and von Willebrand factor-cleaving metalloprotease activity in Escherichia coli O157:H7-associated hemolytic uremic syndrome. Pediatric Research 2001; 49: 653–659.
10. Remuzzi G. HUS and TTP: variable expression of a single entity. Kidney International 2003; 32: 292–308.
11. Hosler GA, Cusumano AM, Hutchins GM. Thrombotic thrombocytopenic purpura and hemolytic uremic syndrome are distinct pathologic entities. A review of 56 autopsy cases. Archives of Pathology and Laboratory Medicine 2003; 127; 834–839.
12. Dlott JS, et al. Drug-induced thrombotic thrombocytopenic purpura/hemolytic uremic syndrome: a concise review. Therapeutic Apheresis and Dialysis 2004; 8: 102–111.
13. Sadler JE, et al. Recent advances in thrombotic thrombocytopaenic purpura. Hematology (American Society of Hematology Education Program) 2004, pp. 407–423.
14. Stewart WC, et al. Survey of zoonoses recorded in Scotland between 1993 and 2002. Veterinary Record 2005; 157: 697–702.
15. Ake JA, et al. Relative nephroprotection during Escherichia coli O157:H7 infections: association with intravenous volume expansion. Pediatrics 2005; 115: 673–680.
16. Marques MB, Mayfield CA, Blackall DP. Thrombotic thrombocytopenic purpura: from platelet aggregates to plasma. American Journal of Clinical Pathology 2004; 121: S89–S96.
17. Wong CS, et al. The risk of hemolytic uremic syndrome after antibiotic treatment of Escherichia coli O157:H7 infections. New England Journal of Medicine 2000; 342: 1930–1936.
18. Vesely SK, et al. ADAMTS-13 activity in thrombotic thrombocytopaenic purpura-hemolytic uremic syndrome: relation to presenting features and clinical outcomes in a prospective cohort of 142 patients. Blood 2003; 102: 60–68.
19. Bell WR, et al. Improved survival in thrombotic thrombocytopaenic purpura-hemolytic uremic syndrome. Clinical experience in 108 patients. New England Journal of Medicine 1991; 325: 398–403.
20. Zakarija A, et al. Clopidogrel-associated TTP. Stroke 2004; 35: 533–538.
21. Brandt JR, et al. Cholethiasis following Escherichia coli O157:H7-associated hemolytic uremic syndrome. Pediatric Nephrology 1998; 12: 222–225.
22. Van Dyck M, Proesmans W, Depraetere M. Hemolytic uremic syndrome in childhood: renal function ten years later. Clinical Nephrology 1988; 29: 109–112.
23. Fitzpatrick MM, Shah VS, Trompeter RS. Long-term renal outcome of childhood haemolytic uraemic syndrome. British Medical Journal 1991; 303: 489–492.
24. Garg AX, et al. Risk of hypertension and reduced kidney function after acute gastro-enteritis from bacteria-contaminated drinking water. Canadian Medical Association Journal 2005; 173: 261–268.